The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis

18Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual data from 1102 patients and 72 healthy volunteers studied in the pre-registration trials. We show that tafenoquine dose is the primary determinant of efficacy. Under an Emax model, we estimate the currently recommended 300 mg dose in a 60 kg adult (5 mg/kg) results in 70% of the maximal obtainable hypnozoiticidal effect. Increasing the dose to 7.5 mg/kg (i.e. 450 mg) would result in 90% reduction in the risk of P. vivax recurrence. After adjustment for dose, the tafenoquine terminal elimination half-life, and day 7 methaemoglobin concentration, but not the parent compound exposure, were also associated with recurrence. These results suggest that the production of oxidative metabolites is central to tafenoquine’s hypnozoiticidal efficacy. Clinical trials of higher tafenoquine doses are needed to characterise their efficacy, safety and tolerability.

References Powered by Scopus

brms: An R package for Bayesian multilevel models using Stan

5756Citations
N/AReaders
Get full text

Genetic and environmental factors in relative body weight and human adiposity

1228Citations
N/AReaders
Get full text

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models

1180Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Malaria

60Citations
N/AReaders
Get full text

Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected with Plasmodium falciparum

10Citations
N/AReaders
Get full text

Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study

10Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Watson, J. A., Commons, R. J., Tarning, J., Simpson, J. A., Cuentas, A. L., Lacerda, M. V. G., … White, N. J. (2022). The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis. ELife, 11. https://doi.org/10.7554/ELIFE.83433

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

62%

Researcher 4

31%

Professor / Associate Prof. 1

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

50%

Immunology and Microbiology 3

25%

Biochemistry, Genetics and Molecular Bi... 2

17%

Pharmacology, Toxicology and Pharmaceut... 1

8%

Article Metrics

Tooltip
Mentions
News Mentions: 6
Social Media
Shares, Likes & Comments: 9

Save time finding and organizing research with Mendeley

Sign up for free